©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 21, 2018; 24(3): 315-322
Published online Jan 21, 2018. doi: 10.3748/wjg.v24.i3.315
Published online Jan 21, 2018. doi: 10.3748/wjg.v24.i3.315
Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates
Chiranjeevi Gadiparthi, Sanjaya K Satapathy, Satheesh Nair, Division of Gastroenterology and Hepatology, University of Tennessee Health Sciences Center, Memphis, TN 38104, United States
George Cholankeril, Aijaz Ahmed, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94304, United States
Brandon J Perumpail, Drexel University College of Medicine, Philadelphia, PA 19129, United States
Eric R Yoo, Department of Medicine, Santa Clara Valley Medical Center, San Jose, CA 95128, United States
Author contributions: All authors contributed to study concept and design, acquisition of data, analysis and interpretation of data, drafting, editing, and critical revision of manuscript and, and approval of final version.
Conflict-of-interest statement: The authors have no conflict of interest related to this publication.
Correspondence to: Aijaz Ahmed, MD, Associate Professor, Attending Doctor, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, 750 Welch Road, Suite 210, Palo Alto, CA 94304, United States. aijazahmed@stanford.edu
Telephone: +1-650-4986091 Fax: +1-650-4985692
Received: November 7, 2017
Peer-review started: November 7, 2017
First decision: November 30, 2017
Revised: December 5, 2017
Accepted: December 12, 2017
Article in press: December 12, 2017
Published online: January 21, 2018
Processing time: 73 Days and 6.4 Hours
Peer-review started: November 7, 2017
First decision: November 30, 2017
Revised: December 5, 2017
Accepted: December 12, 2017
Article in press: December 12, 2017
Published online: January 21, 2018
Processing time: 73 Days and 6.4 Hours
Core Tip
Core tip: Optimal timing of antiviral therapy for hepatitis C virus (HCV) infection in liver transplant candidates using second generation direct-acting antivirals is debated. Available evidence lacks conviction if the viral eradication is beneficial in all HCV patients before liver transplantation. We aim to review the current literature to better delineate the appropriate timing of HCV treatment in the era of direct-acting antiviral agents.